Payment overview · 2025
General Payments
$25,801.75
38 reported records · 9 companies
Healthcare provider profile · identity verified
Joseph K Schoeber, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CASPER, WY · NPI 1740233071
Verified facts
What the public records show
CMS Open Payments records show Joseph K Schoeber, M.D. received $25,801.75 in general payments during 2025 across 38 reported records.
Takeda Pharmaceuticals U.S.A., Inc. accounted for 98.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $25,300.00 | 98.1% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $159.75 | 0.6% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $139.60 | 0.5% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $73.05 | 0.3% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $38.05 | 0.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $37.32 | 0.1% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.33 | 0.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.08 | 0.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.57 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $25,300.00 | 11 |
| Food and Beverage | $480.76 | 25 |
| Education | $20.99 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $139.60 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $73.05 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $73.05 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $72.26 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $66.04 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $38.05 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $37.32 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $37.32 | 2 | 2025 |
Source payment records
|
|||||
| LILETTA Normalized: liletta |
Drug | ABBVIE INC. | $21.45 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $21.33 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $15.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 153 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 77 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
59 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
86 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
77 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
153 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
86 | 16 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
102 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
192 | 36 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 654 | 137 |
| Amlodipine Besylate | Amlodipine Besylate | 643 | 134 |
| Losartan Potassium | Losartan Potassium | 507 | 133 |
| Metoprolol Succinate | Metoprolol Succinate | 498 | 105 |
| Omeprazole | Omeprazole | 498 | 116 |
| Gabapentin | Gabapentin | 447 | 80 |
| Glipizide Er | Glipizide | 416 | 85 |
| Simvastatin | Simvastatin | 411 | 109 |
| Hydrochlorothiazide | Hydrochlorothiazide | 390 | 91 |
| Furosemide | Furosemide | 357 | 70 |
| Lisinopril | Lisinopril | 351 | 86 |
| Atorvastatin Calcium | Atorvastatin Calcium | 332 | 87 |
| Tamsulosin Hcl | Tamsulosin Hcl | 288 | 71 |
| Trazodone Hcl | Trazodone Hcl | 279 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 253 | 67 |
| Sertraline Hcl | Sertraline Hcl | 247 | 55 |
| Escitalopram Oxalate | Escitalopram Oxalate | 245 | 51 |
| Metformin Hcl | Metformin Hcl | 226 | 52 |
| Eliquis | Apixaban | 192 | 36 |
| Potassium Chloride | Potassium Chloride | 166 | 40 |
| Allopurinol | Allopurinol | 156 | 44 |
| Mounjaro | Tirzepatide | 153 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 143 | 36 |
| Montelukast Sodium | Montelukast Sodium | 132 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 129 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 106 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 104 | 89 |
| Clopidogrel | Clopidogrel Bisulfate | 103 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 103 | 21 |
| Ozempic | Semaglutide | 102 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 97 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 93 | 28 |
| Meloxicam | Meloxicam | 90 | 25 |
| Farxiga | Dapagliflozin Propanediol | 86 | 16 |
| Trulicity | Dulaglutide | 86 | 16 |
| Tramadol Hcl | Tramadol Hcl | 84 | 23 |
| Myrbetriq | Mirabegron | 82 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 81 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 77 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 76 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 75 | 12 |
| Alendronate Sodium | Alendronate Sodium | 74 | 21 |
| Bupropion Xl | Bupropion Hcl | 73 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 13 |
| Pregabalin | Pregabalin | 69 | 12 |
| Glimepiride | Glimepiride | 68 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 67 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 60 | suppressed |
| Carvedilol | Carvedilol | 59 | 13 |
| Januvia | Sitagliptin Phosphate | 59 | suppressed |
| Synthroid | Levothyroxine Sodium | 59 | 17 |
| Celecoxib | Celecoxib | 58 | 12 |
| Valacyclovir | Valacyclovir Hcl | 57 | 19 |
| Glipizide | Glipizide | 56 | suppressed |
| Risperidone | Risperidone | 55 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 53 | 13 |
| Spironolactone | Spironolactone | 53 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | 11 |
| Lorazepam | Lorazepam | 52 | suppressed |
| Levetiracetam | Levetiracetam | 51 | suppressed |
| Prednisone | Prednisone | 51 | 38 |
| Warfarin Sodium | Warfarin Sodium | 51 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 49 | suppressed |
| Finasteride | Finasteride | 47 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | 11 |
| Atenolol | Atenolol | 46 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 45 | 12 |
| Jardiance | Empagliflozin | 45 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 44 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 43 | 11 |
| Memantine Hcl | Memantine Hcl | 43 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 43 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 42 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 41 | suppressed |
| Digoxin | Digoxin | 37 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Gemfibrozil | Gemfibrozil | 36 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 36 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 34 | suppressed |
| Cephalexin | Cephalexin | 33 | 22 |
| Methocarbamol | Methocarbamol | 32 | 18 |
| Temazepam | Temazepam | 32 | suppressed |
| Alprazolam | Alprazolam | 31 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Estradiol | Estradiol | 31 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 31 | suppressed |
| Trimethoprim | Trimethoprim | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 25 |
| Ondansetron Hcl | Ondansetron Hcl | 30 | suppressed |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 29 | 27 |
| Doxepin Hcl | Doxepin Hcl | 28 | suppressed |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 16 |
| Galantamine Er | Galantamine Hbr | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Testosterone | Testosterone | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 22 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Famotidine | Famotidine | 22 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 22 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 22 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Nystatin | Nystatin | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 15 |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Pentoxifylline | Pentoxifylline | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Colchicine | Colchicine | 19 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 17 |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Dulera | Mometasone/Formoterol | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Hydroxyurea | Hydroxyurea | 15 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Indapamide | Indapamide | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 14 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Klor-Con M15 | Potassium Chloride | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 12 | suppressed |
| Cholestyramine Light | Cholestyramine | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 11 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | 11 |
| Humulin R | Insulin Regular, Human | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $25,801.75 · 38 records | Takeda Pharmaceuticals U.S.A., Inc. | BREZTRI, CAPVAXIVE, ENFLONSIA, GARDASIL 9, LILETTA, MOUNJARO, NURTEC ODT, QULIPTA, REXULTI, TRELEGY ELLIPTA, VAXNEUVANCE, VRAYLAR, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error